Journal of the American Academy of Dermatology
Volume 56, Issue 1 , Pages 27-30 , January 2007

Gadolinium deposition in nephrogenic fibrosing dermopathy

  • Alan S. Boyd, MD

      Affiliations

    • From the Departments of Medicine (Dermatology)
    • Pathology, Vanderbilt University, Nashville
    • Corresponding Author InformationCorrespondence to: Alan S. Boyd, MD, 3900 The Vanderbilt Clinic, Nashville, TN 37232.
    • ,
  • John A. Zic, MD

      Affiliations

    • From the Departments of Medicine (Dermatology)
    • ,
  • Jerrold L. Abraham, MD

      Affiliations

    • Department of Pathology, SUNY Upstate Medical University, Syracuse

,Accepted 27 October 2006.

References 

  1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000–1001
  2. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383–391
  3. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  4. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–2362
  5. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthr Rheum. 2006;35:238–249
  6. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903–909
  7. Cowper SE, Bucala R, LeBoit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis—setting the record straight. Semin Arthr Rheum. 2005;35:208–210
  8. Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy; a new pathogenic hypothesis. Br J Dermatol. 2004;150:1050–1052
  9. Spencer A, Wilson S, Batchelor J, Reid A, Rees J, Harpur E. Gadolinium chloride toxicity in the rat. Toxicol Pathol. 1997;25:245–255
  10. Center for Drug Evaluation and Research. US Food and Drug Administration Web site. Public health advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance (June 8, 2006). Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed October 30, 2006.

 Funding sources: None.Conflicts of interest: None identified.Reprints not available from the authors.

PII: S0190-9622(06)02878-7

doi: 10.1016/j.jaad.2006.10.048

Journal of the American Academy of Dermatology
Volume 56, Issue 1 , Pages 27-30 , January 2007

Article Tools

* Image Usage & Resolution